Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?
Steffen Pabel, Nazha Hamdani, Mark Luedde, et al.
Current Heart Failure Reports (2021) Vol. 18, Iss. 5, pp. 315-328
Open Access | Times Cited: 76

Showing 1-25 of 76 citing articles:

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3651-3651
Open Access | Times Cited: 149
Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
Arjun Pandey, Deepak L. Bhatt, Avinash Pandey, et al.
European Heart Journal (2023) Vol. 44, Iss. 37, pp. 3640-3651
Closed Access | Times Cited: 37
Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients – DACAMI (a randomized controlled clinical trial)
Khairy Abdel Dayem, Omar Younis, Bassem Zarif, et al.
International Journal of Cardiology (2023) Vol. 379, pp. 9-14
Closed Access | Times Cited: 27
Guideline-Directed Medical Therapy for the Treatment of Heart Failure with Reduced Ejection Fraction
Jay Patel, Negin Rassekh, Gregg C. Fonarow, et al.
Drugs (2023) Vol. 83, Iss. 9, pp. 747-759
Closed Access | Times Cited: 23
Insulin resistance/hyperinsulinemia: an important cardiovascular risk factor that has long been underestimated
Sergio Fazio, Valentina Mercurio, Loredana Tibullo, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 12
Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium–glucose cotransporter 2 inhibitors
Paul J.M. Wijnker, Rafeeh Dinani, Nico C van der Laan, et al.
Cardiovascular Research (2024) Vol. 120, Iss. 3, pp. 301-317
Open Access | Times Cited: 9
Endothelial Dysfunction in Heart Failure With Preserved Ejection Fraction: What are the Experimental Proofs?
Lauriane Cornuault, Paul Rouault, Cécile Duplaà, et al.
Frontiers in Physiology (2022) Vol. 13
Open Access | Times Cited: 35
Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy
Ren Jie Phang, Rebecca H. Ritchie, Derek J. Hausenloy, et al.
Cardiovascular Research (2022) Vol. 119, Iss. 3, pp. 668-690
Open Access | Times Cited: 32
Cellular Metabolism: A Fundamental Component of Degeneration in the Nervous System
Kenneth Maiese
Biomolecules (2023) Vol. 13, Iss. 5, pp. 816-816
Open Access | Times Cited: 21
The impact of aging and oxidative stress in metabolic and nervous system disorders: programmed cell death and molecular signal transduction crosstalk
Kenneth Maiese
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 20
Precision Cardiology: Phenotype-targeted Therapies for HFmrEF and HFpEF
Giuseppe Rosano, Cristiana Vitale, Ilaria Spoletini
International Journal of Heart Failure (2024) Vol. 6, Iss. 2, pp. 47-47
Open Access | Times Cited: 8
Empagliflozin Improves Diastolic Function in HFpEF by Restabilizing the Mitochondrial Respiratory Chain
Antje Schauer, Volker Adams, Susanne Kämmerer, et al.
Circulation Heart Failure (2024) Vol. 17, Iss. 6
Open Access | Times Cited: 8
Tuberculosis-diabetes comorbidities: Mechanistic insights for clinical considerations and treatment challenges
Md. Abdul Alim Al‐Bari, Nicholas Peake, Nabil Eid
World Journal of Diabetes (2024) Vol. 15, Iss. 5, pp. 853-866
Open Access | Times Cited: 7
The Metabolic Basis for Nervous System Dysfunction in Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease
Kenneth Maiese
Current Neurovascular Research (2023) Vol. 20, Iss. 3, pp. 314-333
Open Access | Times Cited: 15
Cardiometabolic effects of SGLT2 inhibitors on polycystic ovary syndrome
Ioannis Lempesis, Samuel J. Apple, Gustavo Duarte, et al.
Diabetes/Metabolism Research and Reviews (2023) Vol. 39, Iss. 6
Open Access | Times Cited: 14
SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect. State of the Art
David Aristizábal-Colorado, Martín Ocampo Posada, Wilfredo Antonio Rivera Martínez, et al.
American Journal of Cardiovascular Drugs (2024) Vol. 24, Iss. 6, pp. 707-718
Closed Access | Times Cited: 5
Efficacy of sacubitril‐valsartan and SGLT2 inhibitors in heart failure with reduced ejection fraction: A systematic review and meta‐analysis
Xingchun Mo, Ping Lü, Xiaojing Yang
Clinical Cardiology (2023) Vol. 46, Iss. 10, pp. 1137-1145
Open Access | Times Cited: 12
Clinical pharmacology of SGLT-2 inhibitors in heart failure
Maria Velliou, Effie Polyzogopoulou, Ioannis Ventoulis, et al.
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 2, pp. 149-160
Closed Access | Times Cited: 11
Cognitive Impairment in Multiple Sclerosis
Kenneth Maiese
Bioengineering (2023) Vol. 10, Iss. 7, pp. 871-871
Open Access | Times Cited: 11
Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis
Ahmed E. Ali, Muhammad S Mazroua, Mariam ElSaban, et al.
Global Heart (2023) Vol. 18, Iss. 1, pp. 45-45
Open Access | Times Cited: 11
Cornerstone Cellular Pathways for Metabolic Disorders and Diabetes Mellitus: Non-Coding RNAs, Wnt Signaling, and AMPK
Kenneth Maiese
Cells (2023) Vol. 12, Iss. 22, pp. 2595-2595
Open Access | Times Cited: 11
SGLT2 Inhibition in Heart Failure: Clues to Cardiac Effects?
Patrick Savage, Lana Dixon, David J. Grieve, et al.
Cardiology in Review (2024)
Open Access | Times Cited: 4
Cardiovascular outcomes of SGLT-2 inhibitors’ subtypes in type 2 diabetes; an updated systematic review and meta-analysis of randomized controlled trials
Pouya Ebrahimi, Hamidreza Soleimani, Mehrdad Mahalleh, et al.
Journal of Diabetes & Metabolic Disorders (2025) Vol. 24, Iss. 1
Closed Access
Empagliflozin in diabetic cardiomyopathy: elucidating mechanisms, therapeutic potentials, and future directions
Aiswarya Jaiswal, Poonam Yadav, Pushkar Singh Rawat, et al.
Molecular Biology Reports (2025) Vol. 52, Iss. 1
Closed Access
Single cell transcriptomic analysis of SGLT2 expression supports an indirect or off-target role for the cardioprotective benefits of empagliflozin in heart failure
Omar Mourad, Shabana Vohra, Sara S. Nunes
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top